At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Baloxavir Marboxildrug
Likely dose
Baloxavir Marboxil 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-Centre, Open-Label, Parallel, Two Dose Level Study to Investigate the Pharmacokinetics, Safety, and Tolerability Following a Single Dose of Baloxavir Marboxil in Healthy Chinese Volunteers
In Brief
A clinical study evaluating Baloxavir Marboxil for Healthy Volunteer. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer
CountriesChina
CollaboratorsShionogi
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionJul 2019
TodayJul 2026
First PostedMay 22, 2019
Enrollment StartJun 19, 2019
Primary CompletionJul 11, 2019
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 7.1 years ago
Interventions
Baloxavir Marboxildrug
Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.